Original paper
Brivanib in combination with Notch3 silencing shows potent activity in tumour models
Abstract
Sorafenib is the first targeted agent proven to improve survival of patients with advanced hepatocellular carcinoma (HCC) and it has been used in first line treatments with heterogeneous response across patients. Most of the promising agents evaluated in first-line or second-line phase III trials for HCC failed to improve patient survival. The absence of molecular characterisation, including the identification of pathways driving resistance...
Paper Details
Title
Brivanib in combination with Notch3 silencing shows potent activity in tumour models
Published Date
Feb 15, 2019
Journal
Volume
120
Issue
6
Pages
601 - 611
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History